DOCSLIB.ORG

United States Patent Office Patented Dec

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent Office Patented Dec 2,963,402 United States Patent Office Patented Dec. 6, 1960 2 an improved explosion hazard-free medicament whose 2,963,402 active ingredient is of a highly explosive nature and present in relatively high concentrations, and is released SUSTAINED RELEASE MEDICAMENT when administered over extended periods of time. Edward Nalin, 520 E. 83rd St., New York, N.Y., Eugene 5 Still another object of the present invention is to pro J. Yoss, Forest Hills, Milton Sacks and Ira Sacks, East vide an improved timed release medicament whose active Meadow, and Max Smedresman, Long Island City, ingredient is of a highly explosive nature, which medic N.Y.; said Yoss, M. Sacks, I. Sacks, and Smedresman ament may be produced with a minimum explosive assignors to Nysco Laboratories, Inc., Long Island hazard. City, N.Y., a corporation of New York O A further object of the present invention is to provide No Drawing. Filed Jan. 18, 1955, Ser, No. 482,651 an improved method for producing timed disintegration capsules having an active ingredient of a highly explosive 4 Claims. (Cl. 167-82) nature. It is a feature of the present invention to provide a The present invention relates generally to an improved 15 medicament comprising a pellet of innocuous material form of medicament for oral administration and an im: carrying in an intimately admixed state a normally ex proved method for preparing the same. It relates more plosive, physiologically active substance and a desensi particularly to an improved medicament of the timed tizing vehicle, said active ingredient-carrying pellet being disintegration type for oral administration. covered by a coating disintegratable in the body fluids. There are many organic disorders which require for 20 The normally explosive physiologically active ingredient their treatment nitrate compounds which are normally may partially or wholly impregnate the pellet or may highly explosive. For example, in the treatment of form a coating thereon impregnating the pellet to a greater cardiac conditions, it is common practice to orally ad or lesser depth to form a firm bond thereto. It has been minister, nitroglycerin, mannitol hexanitrate, pentaery found that pellets of this type may be produced with a thritol tetranitrate, or similar compounds. These sub 25 high concentration of normally explosive active ingre stances are physiologically characterized by their vaso dients without explosion danger or hazard and that the dilator action thereby causing persistent relaxation of the end, product is perfectly safe in this respect. Pellets smooth muscle and the smaller blood vessels, a fall in having disintegratable coatings of various thicknesses blood pressure and a reduction in hypertension. How are admixed and carried in gelatin capsules so that the ever, their physiological effects are normally experienced 30 active ingredients are released over a prolonged period: for a period only of approximately two hours after oral of time. - administration, and the dose must thus be regularly re The pellets, per se, are produced in the conventional peated. The active ingredients are usually admixed with finanner and are of generally spherical shape and prefera. an inert carrier, and formed into tablets having a rela ably of a size between 8 and 40 mesh per inch. The tively low percentage of the active ingredient. 35 pellets should be formed of an innocuous, disintegratable Since medicinal substances of the above type require excipient such as milk sugar, cane sugar, dicalcium phos regular and continuous administration because of their phate, mannitol, sorbitol, or any other suitable excipient, limited time of effectiveness, it is highly desirable to pro organic or inorganic. The normally explosive active in duce the medicament in a form wherein the active in gredient may be mannitol hexanitrate, erythritol tetra gredients are released over an extended period, so as 40 nitrate, pentaerythritol tetranitrate nitroglycerine, inositol to obviate the necessity for the continuous repeated ad hexanitrate, or other explosive physiologically active in ministration thereof. Such medicament, if in the form of gredient. The desensitizing vehicle may be a pharma the so-called timed disintegration capsules, would provide ceutical glaze such as shellac, a natural wax. Such as great advantages and convenience. The timed disintegra beeswax or carnauba wax, a synthetic wax or cellulose tion capsule generally consists of a gelatin capsule carry 45 acetate phthalate, or other suitable cellulose derivative, ing a plurality of small pellets containing the active in or any other innocuous desensitizing material which is gredients, the pellets being covered with coatings which compatible with the active ingredients. disintegrate in the body fluids. The pellet coatings are In applying the desensitizing vehicle-carried active of various thickness so that their disintegration-and the ingredient to the ?pellets, the active ingredient and the release of the active ingredients extends over any de 50 desensitizing vehicle are admixed in a volatile liquid sired period. Such timed disintegration capsules are dis in which they are miscible and preferably soluble, such closed in Australian Patent No. 109,438 issued in 1938. as acetone, chloroform, ether or the like. A measured However, by reason of the highly explosive nature of quantity of the pellets, which may be of uniform or vary the physiologically active nitrated organic compounds, it ing sizes, are deposited in a suitable mixer. The solution has been heretofore impossible to produce a medicament 55 or mixture of the active ingredient and desensitizing ve containing such substance in a form in which the active hicle in the volatile liquid is then added to the mixer to ingredient is released over a relatively long period of effect a uniform distribution of the active ingredients time. and vehicle onto the pellets. Upon evaporation of the It is thus a principal object of the present invention liquid, the active ingredients distributed in the vehicle to provide an improved medicament. 60 forms a coating on the pellets, partially impregnating the Another object of the present invention is to provide pellets and firmly bonded thereto. The concentration an improved medicament whose physiologically active of the active ingredient depends on the dosage require ingredient is of a highly explosive nature. ments and it has been found that as high as an 11% Still another object of the present invention is to pro concentration or higher of mannitol hexanitrate based vide an improved form of medicament in which the ac 65 on the total weight of the medicament, is completely safe tive ingredients are released over extended periods of in its explosive properties. The relative proportions of time. the vehicle and the active ingredient may vary, a ratio A further object of the present invention is to provide of about 1 part vehicle to 3 parts active ingredient having an improved medicament whose active ingredient is of been found satisfactory and safe. a highly explosive nature, and is released when adminis 70 Disintegratable coatings are then applied to the active tered over extended periods of time. pellets. These coatings may be formed of a pharma Another object of the present invention is to provide ceutical glaze, such as shellac or natural or synthetic 2,968,402 , - - - 3 4. wax or cellulose acetate phthalate each of which are explosive ingredient or may be supplied on separate enteric in nature. The thickness of the coatings of the pellets. Furthermore, the coated pellets may be further pellets varies in a predetermined manner so that the coat coated with a layer of sugar, either colored or uncolored. ings disintegrate in the body fluids, in the stomach or We claim: intestines as desired over a predetermined prolonged 1. An improved medicament for oral administration period. The pellets are then packaged in gelatin cap comprising a pellet of innocuous material, a layer of a sules in the desired dosage and time range, a portion normally explosive, physiologically active ingredient in of the pellets being free of the disintegratable coatings timately admixed with and carried by a pharmaceutical so as to free the active ingredients almost immediately. glaze Superimposed upon said pellet, said active ingre As a specific example of the present invention, substan 10 dient being selected from the class consisting of mannitol tially spherical pellets of approximately 1 millimeter in hexanitrate, erythritol tetranitrate, pentaerythritol tetra diameter are formed of 80% cane sugar and 20% corn nitrate, nitroglycerine, and inositol hexanitrate and said starch in the conventional manner. pharmaceutical glaze being selected from the class con 178 pounds of the pellets are placed in a conventional sisting of shellac, natural wax, synthetic wax and cellulose type ribbon mixer to which is added an acetonic solution 5 acetate phthalate, said layer-carrying pellet being covered of shellac and mannitol hexanitrate. This latter solu with a phermaceutical glaze. tion comprises approximately 64 pounds shellac, 22% 2. An improved medicament for oral administration pounds mannitol hexanitrate, 4 quarts ethanol and 9 comprising a plurality of pellets formed of an innocuous quarts acetone. Following the complete and uniform material, a layer of normally explosive physiologically coating of the pellets they are then placed in a dryer to 20 active ingredient intimately admixed with and carried by completely evaporate the solvents. a pharmaceutical glaze
Load more

Recommended publications
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Nitric Oxide Releasing Chelating Agents and Their
    Europäisches Patentamt *EP001060174B1* (19) European Patent Office Office européen des brevets (11) EP 1 060 174 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07D 401/12, A61K 31/44 of the grant of the patent: 22.09.2004 Bulletin 2004/39 (86) International application number: PCT/GB1998/003840 (21) Application number: 98962567.8 (87) International publication number: (22) Date of filing: 18.12.1998 WO 1999/033823 (08.07.1999 Gazette 1999/27) (54) NITRIC OXIDE RELEASING CHELATING AGENTS AND THEIR THERAPEUTIC USE STICKSTOFFOXID FREISETZENDE CHELATBILDNER UND IHRE THERAPEUTISCHE VERWENDUNG CHELATEURS LIBERANT DE L’OXYDE NITRIQUE ET LEUR EMPLOI A DES FINS THERAPEUTIQUES (84) Designated Contracting States: (74) Representative: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Hammett, Audrey Grace Campbell et al MC NL PT SE Amersham plc Amersham Place (30) Priority: 23.12.1997 GB 9727226 Little Chalfont, Bucks. HP7 9NA (GB) 13.03.1998 GB 9805450 (56) References cited: (43) Date of publication of application: EP-A- 0 292 761 WO-A-93/20806 20.12.2000 Bulletin 2000/51 WO-A-95/12394 WO-A-96/31217 WO-A-96/39409 WO-A-97/49390 (73) Proprietor: Amersham Health AS US-A- 5 250 550 0401 Oslo (NO) • MOORADIAN D L ET AL: "NITRIC OXIDE (NO) (72) Inventors: DONOR MOLECULES: EFFECT OF NO • TOWART, Robertson RELEASE RATE ON VASCULAR SMOOTH Stoke Poges SL2 4PT (GB) MUSCLE CELL PROLIFERATION IN VITRO" • KARLSSON, Jan, Olof, Gustav JOURNAL OF CARDIOVASCULAR N-1450 Nesoddtangen (NO) PHARMACOLOGY, vol.
    [Show full text]
  • Potentially Explosive Chemicals*
    Potentially Explosive Chemicals* Chemical Name CAS # Not 1,1’-Diazoaminonaphthalene Assigned 1,1-Dinitroethane 000600-40-8 1,2,4-Butanetriol trinitrate 006659-60-5 1,2-Diazidoethane 000629-13-0 1,3,5-trimethyl-2,4,6-trinitrobenzene 000602-96-0 1,3-Diazopropane 005239-06-5 Not 1,3-Dinitro-4,5-dinitrosobenzene Assigned Not 1,3-dinitro-5,5-dimethyl hydantoin Assigned Not 1,4-Dinitro-1,1,4,4-tetramethylolbutanetetranitrate Assigned Not 1,7-Octadiene-3,5-Diyne-1,8-Dimethoxy-9-Octadecynoic acid Assigned 1,8 –dihydroxy 2,4,5,7-tetranitroanthraquinone 000517-92-0 Not 1,9-Dinitroxy pentamethylene-2,4,6,8-tetramine Assigned 1-Bromo-3-nitrobenzene 000585-79-5 Not 2,2',4,4',6,6'-Hexanitro-3,3'-dihydroxyazobenzene Assigned 2,2-di-(4,4,-di-tert-butylperoxycyclohexyl)propane 001705-60-8 2,2-Dinitrostilbene 006275-02-1 2,3,4,6- tetranitrophenol 000641-16-7 Not 2,3,4,6-tetranitrophenyl methyl nitramine Assigned Not 2,3,4,6-tetranitrophenyl nitramine Assigned Not 2,3,5,6- tetranitroso nitrobenzene Assigned Not 2,3,5,6- tetranitroso-1,4-dinitrobenzene Assigned 2,4,6-Trinitro-1,3,5-triazo benzene 029306-57-8 Not 2,4,6-trinitro-1,3-diazabenzene Assigned Not 2,4,6-Trinitrophenyl trimethylol methyl nitramine trinitrate Assigned Not 2,4,6-Trinitroso-3-methyl nitraminoanisole Assigned 2,4-Dinitro-1,3,5-trimethyl-benzene 000608-50-4 2,4-Dinitrophenylhydrazine 000119-26-6 2,4-Dinitroresorcinol 000519-44-8 2,5-dimethyl-2,5-diydroperoxy hexane 2-Nitro-2-methylpropanol nitrate 024884-69-3 3,5-Dinitrosalicylic acid 000609-99-4 Not 3-Azido-1,2-propylene glycol dinitrate
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Prediction of the Crystalline Densities of Aliphatic Nitrates by Quantum Chemistry Methods
    Central European Journal of Energetic Materials ISSN 1733-7178; e-ISSN 2353-1843 Copyright © 2019 Sieć Badawcza Łukasiewicz – Institute of Industrial Organic Chemistry, Poland Cent. Eur. J. Energ. Mater. 2019, 16(3): 412-432; DOI 10.22211/cejem/112306 Article is available in PDF-format, in colour, at: http://www.wydawnictwa.ipo.waw.pl/cejem/Vol-16-Number3-2019/CEJEM_00978.pdf Article is available under the Creative Commons Attribution-Noncommercial-NoDerivs 3.0 license CC BY-NC-ND 3.0. Research paper Prediction of the Crystalline Densities of Aliphatic Nitrates by Quantum Chemistry Methods Guixiang Wang,* Yimin Xu, Chuang Xue, Zhiyuan Ding, Yan Liu, Hui Liu, Xuedong Gong** Computation Institute for Molecules and Materials, Department of Chemistry, Nanjing University of Science and Technology, Nanjing 210094, China E-mails: * [email protected]; ** [email protected] Abstract: Crystal density is a basic and important parameter for predicting the detonation performance of explosives, and nitrate esters are a type of compound widely used in the military context. In this study, thirty-one aliphatic nitrates were investigated using the density functional theory method (B3LYP) in combination with six basis sets (3-21G, 6-31G, 6-31G*, 6-31G**, 6-311G* and 6-31+G**) and the semiempirical molecular orbital method (PM3). Based on the geometric optimizations at various theoretical levels, the molecular volumes and densities were calculated. Compared with the available experimental data, the densities calculated by various methods are all overestimated, and the errors of the PM3 and B3LYP/3-21G methods are larger than those of other methods. Considering the results and the computer resources required by the calculations, the B3LYP/6-31G* method is recommended for predicting the crystalline densities of organic nitrates using a fitting equation.
    [Show full text]
  • Compositions Comprising Nebivolol
    (19) TZZ ZZ__T (11) EP 2 808 015 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 03.12.2014 Bulletin 2014/49 A61K 31/34 (2006.01) A61K 31/502 (2006.01) A61K 31/353 (2006.01) A61P 9/00 (2006.01) (21) Application number: 14002458.9 (22) Date of filing: 16.11.2005 (84) Designated Contracting States: • O’Donnell, John AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Morgantown, WV 26505 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Bottini, Peter Bruce SK TR Morgantown, WV 26505 (US) • Mason, Preston (30) Priority: 31.05.2005 US 141235 Morgantown, WV 26504 (US) 10.11.2005 US 272562 • Shaw, Andrew Preston 15.11.2005 US 273992 Morgantown, WV 26504 (US) (62) Document number(s) of the earlier application(s) in (74) Representative: Samson & Partner accordance with Art. 76 EPC: Widenmayerstraße 5 09015249.7 / 2 174 658 80538 München (DE) 05848185.4 / 1 890 691 Remarks: (71) Applicant: MYLAN LABORATORIES, INC This application was filed on 16-07-2014 as a Morgantown, NV 26504 (US) divisional application to the application mentioned under INID code 62. (72) Inventors: • Davis, Eric Morgantown, WV 26508 (US) (54) Compositions comprising nebivolol (57) The active ingredients of the pharmaceutical composition described consist of nebivolol, one or more ACE inhibitors and one or more ARB. EP 2 808 015 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 808 015 A1 Description [0001] This application is a continuation-in-part of application Ser.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,391,895 B1 Towart Et Al
    USOO639 1895B1 (12) United States Patent (10) Patent No.: US 6,391,895 B1 Towart et al. (45) Date of Patent: May 21, 2002 (54) NITRICOXIDE RELEASING CHELATING FOREIGN PATENT DOCUMENTS AGENTS AND THER THERAPEUTIC USE WO O 292 761 A 11/1988 WO WO 93 20806 A 10/1993 (75) Inventors: Robertson Towart, Stoke Poges (GB); WO WO 95 12394 A 5/1995 Jan Olof Gustav Karlsson, WO WO 96 31217 A 10/1996 Nesoddtangen (NO); Lars Goran WO WO 96 394O9 A 12/1996 Wistrand; Hakan Malmgren, both of WO WO 97.49390 A 12/1997 Lund (SE) WO 97/494.09 12/1997 ................. 514/335 (73) Assignee: Amersham Health AS, Oslo (NO) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Mooradian D.L. et al., “Nitric Oxide (No) Donor Molecules: patent is extended or adjusted under 35 Effect of No Release Rate on Vascular Smooth Muscle Cell U.S.C. 154(b) by 0 days. Proliferation in Vitro’, Journal of Cardiovascular Pharma cology, Jan. 1, 1995, XP000563583. (21) Appl. No.: 09/599,862 Lefer D.J.: “Myocardial Protective Actions of Nitric Oxide Doors. After Myocardial Ischemia and Reperfusion”, New (22) Filed: Jun. 23, 2000 Horizons, Feb. 1, 1995, XP000575669. Related U.S. Application Data * cited by examiner (63) Continuation of application No. PCT/GB98/03804, filed on Dec. 18, 1998. Primary Examiner-Charanjit S. Aulakh (60) Provisional application No. 60/076.793, filed on Mar. 4, (74) Attorney, Agent, or Firm-Royal N. Ronning, Jr. 1998. (57) ABSTRACT (30) Foreign Application Priority Data Chelating agents, in particular dipyridoxyl and aminopoly Dec.
    [Show full text]
  • United States Patent (10) Patent No.: US 7,235,237 B2 L0scalz0 Et Al
    USOO7235237B2 (12) United States Patent (10) Patent No.: US 7,235,237 B2 L0ScalZ0 et al. (45) Date of Patent: Jun. 26, 2007 (54) METHODS OF TREATING VASCULAR 5,968,983 A 10/1999 Kaesemeyer DISEASES CHARACTERIZED BY NITRC 5,973,011 A 10/1999 Noack et al. OXIDE INSUFFICIENCY 6,103,769 A 8, 2000 Kelm 6,117,872 A 9, 2000 Maxwell et al. (75) Inventors: Joseph Loscalzo, Dover, MA (US); 6,319,515 B1 1 1/2001 Hidaka et al. Joseph A. Vita, Hingham, MA (US); 6,458,797 B1 10/2002 Adams et al. Michael D. Loberg, Boston, MA (US); 2004, OO63719 A1 4/2004 Adams et al. Manuel Worcel, Boston, MA (US) FOREIGN PATENT DOCUMENTS (73) Assignee: NitroMed, Inc., Lexington, MA (US) EP O327263 A 8, 1989 (*) Notice: Subject to any disclaimer, the term of this EP O 968 713 A1 5, 1998 patent is extended or adjusted under 35 JP O905915.2 3, 1997 U.S.C. 154(b) by 492 days. WO WO95/26725 10, 1995 WO WO 98.21 193 5, 1998 (21) Appl. No.: 10/415,136 WO WO 99.00361 1, 1999 WO WO 99,66921 12/1999 (22) PCT Filed: May 2, 2001 WO WO 99,67231 12/1999 WO WO O1/35961 A 5, 2001 (86). PCT No.: PCT/USO1A14245 OTHER PUBLICATIONS S 371 (c)(1), (2), (4) Date: Apr. 25, 2003 Dupuis, Cardiovascular Drugs and Therapy, 8(3):501-507 (1994). Cohn et al. The New England Journal of Medicine, 325(5):303-310 (87) PCT Pub.
    [Show full text]
  • Commerce in Explosives; 2020 Annual Those on the Annual List
    Federal Register / Vol. 85, No. 247 / Wednesday, December 23, 2020 / Notices 83999 inspection at the Office of the Secretary or synonyms in brackets. This list Black powder substitutes. and on EDIS.3 supersedes the List of Explosive *Blasting agents, nitro-carbo-nitrates, This action is taken under the Materials published in the Federal including non-cap sensitive slurry and authority of section 337 of the Tariff Act Register on January 2, 2020 (Docket No. water gel explosives. of 1930, as amended (19 U.S.C. 1337), 2019R–04, 85 FR 128). Blasting caps. and of §§ 201.10 and 210.8(c) of the The 2020 List of Explosive Materials Blasting gelatin. Commission’s Rules of Practice and is a comprehensive list, but is not all- Blasting powder. Procedure (19 CFR 201.10, 210.8(c)). inclusive. The definition of ‘‘explosive BTNEC [bis (trinitroethyl) carbonate]. materials’’ includes ‘‘[e]xplosives, BTNEN [bis (trinitroethyl) nitramine]. By order of the Commission. BTTN [1,2,4 butanetriol trinitrate]. Issued: December 18, 2020. blasting agents, water gels and detonators. Explosive materials, Bulk salutes. William Bishop, include, but are not limited to, all items Butyl tetryl. Supervisory Hearings and Information in the ‘List of Explosive Materials’ Officer. C provided for in § 555.23.’’ 27 CFR Calcium nitrate explosive mixture. [FR Doc. 2020–28458 Filed 12–22–20; 8:45 am] 555.11. Accordingly, the fact that an BILLING CODE 7020–02–P Cellulose hexanitrate explosive explosive material is not on the annual mixture. list does not mean that it is not within Chlorate explosive mixtures. coverage of the law if it otherwise meets DEPARTMENT OF JUSTICE Composition A and variations.
    [Show full text]
  • Characterization of Explosives & Precursors
    Appendix A: Project Reports ALERT Thrust R1: Characterization & Elimination of Illicit Explosives Phase 2 Year 7 Annual Report Project R1-A.1 R1-A.1: Characterization of Explosives & Precursors I. PARTICIPANTS INVOLVED FROM JULY 1, 2019 TO JUNE 30, 2020 Faculty/Staff Name Title Institution Email Jimmie Oxley Co-PI URI [email protected] Jim Smith Co-PI URI [email protected] Gerald Kagan Post-Doc URI [email protected] Graduate, Undergraduate and REU Students Name Degree Pursued Institution Month/Year of Graduation Taylor Busby PhD URI 5/2021 Lindsay McLennan PhD URI 5/2020 Robert Ichiyama PhD URI 5/2023 II. PROJECT DESCRIPTION A. Project Overview This project sought to determine the physical properties, synthesis, and destruction mechanisms of improvised explosives, often called homemade explosives (HMEs). In Year 7, we performed further characterization on erythritol tetranitrate (ETN) and on the nitro-sugars mannitol and sorbitol hexanitrate and HMTD. For ETN, we examined its synthesis and sought stable isotope signatures that might allow attribution to particular groups. For the sugars we are attempting to establish basic properties and observing different polymorphs. The existence of polymorphs was also found with HMTD. B. State of the Art and Technical Approach Stable isotope analysis is a technique capable of determining the subtle differences between the stable isotope ratios of hydrogen (2H/1H), carbon (13C/12C), nitrogen (15N/14N), oxygen (18O/16O), and, with special modifications, sulfur (34S/32S). Stable isotope analyses are important for provenance studies, where minute differences in isotope ratios can determine production location. Stable isotope ratio mass spectrometry (IRMS) has been considered as a forensic science technique for attribution that has been applied to illicit drugs, chemical weapon agents, and recently to explosives.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Federal Register/Vol. 79, No. 194/Tuesday, October 7, 2014
    60496 Federal Register / Vol. 79, No. 194 / Tuesday, October 7, 2014 / Notices Commission rules 210.21(a)(2), (b)(1). DEPARTMENT OF JUSTICE are regulated explosive materials The ALJ also found that there is no regardless of their size or specific indication that termination of the Bureau of Alcohol, Tobacco, Firearms, energetic composition. The addition of investigation in view of the settlement and Explosives this term will not expand the list to agreement would have an adverse [Docket No. 2014R–25T] include any materials not already impact on the public interest. No party covered under other names. ATF petitioned for review of the ID. The Commerce in Explosives; 2014 Annual generally classifies pyrotechnic fuse as Commission has determined not to List of Explosive Materials low explosives subject to the Federal explosives laws and implementing review the ID and has terminated the AGENCY: Bureau of Alcohol, Tobacco, investigation. explosives regulations at 27 CFR Part Firearms, and Explosives (ATF); 555—Commerce in Explosives and the The authority for the Commission’s Department of Justice. U.S. Department of Transportation determination is contained in section ACTION: Notice of list of explosive classifies them as Class 1 explosives. 337 of the Tariff Act of 1930, as materials. External burning pyrotechnic fuses that amended, 19 U.S.C. 1337, and in Part are components of small arms 210 of the Commission’s Rules of SUMMARY: Pursuant to 18 U.S.C. 841(d) ammunition will remain exempt Practice and Procedure, 19 CFR part and 27 CFR 555.23, the Department pursuant to 18 U.S.C.
    [Show full text]